DOCS

Doximity (DOCS) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this medical social networking site, should get reflected in its stock price.

Doximity, Inc. (NYSE:DOCS) Q2 2024 Earnings Call Transcript November 9, 2023. Dr. Nate Gross, Co-Founder and CSO; and Anna Bryson, CFO. Reported EPS is $0.22, expectations were $ 0.18.

Polen Capital, an investment management company, released its “Polen U.S. SMID Company Growth Strategy’ third-quarter 2023 investor letter. Doximity, Inc. (NYSE:DOCS) provides a cloud platform for medical professionals. The portfolio returned 11.68% (net) YTD, compared to 5.63% for the index.

Dr. Martens plc (LON:DOCS) is potentially trading close to its fair value. Analyst price target for DOCS is 16% below our fair value estimate. We use the Discounted Cash Flow (DCF) model to estimate the company's future cash flows.

Doximity Inc. (DOCS) on Tuesday reported fiscal first-quarter earnings of $28.4 million. Earnings, adjusted for one-time gains and costs, came to 19 cents per share. The results topped Wall Street expectations.

The board of Dr. Martens plc (LON:DOCS) has announced that it will pay a dividend on the 18th of July, with investors receiving £0.0428 per share. This means the annual payment is 4.4% of the current stock price, which is above the average for the industry. The last payment was quite easily covered by earnings, but it made up 232% of cash flows.

Dr. Martens (LON:DOCS) has an ROCE of 29%. In absolute terms that's a great return and it's even better than the Luxury industry average of 10%. In the last five years, the returns generated on capital employed have grown considerably to 29%. The amount of capital employed has increased too, by 100%.

Doximity Inc. (DOCS) on Tuesday reported fiscal fourth-quarter earnings of $30.7 million. The results beat Wall Street expectations. For the year, the company reported profit of $112.8 million, or 53 cents per share.

Doximity Inc. (DOCS) on Tuesday reported fiscal fourth-quarter earnings of $30.7 million. The results beat Wall Street expectations. The medical social networking site posted revenue of $111 million in the period.

Doximity Inc. (DOCS) on Tuesday reported fiscal fourth-quarter earnings of $30.7 million. The results beat Wall Street expectations. The medical social networking site posted revenue of $111 million in the period.

Doximity Inc. (DOCS) on Tuesday reported fiscal fourth-quarter earnings of $30.7 million. The results beat Wall Street expectations. The medical social networking site posted revenue of $111 million.

Doximity's (NYSE:DOCS) ROE is 13%, based on the trailing twelve months to December 2022. Doximity doesn't pay any dividend to its shareholders, meaning that the company has been reinvesting all of its profits into the business. The company has seen an impressive net income growth of 66% over the last five years. To know more about the company's future earnings growth forecasts take a look at this free report.

Dr. Martens plc (LON:DOCS) is estimated to be 28% undervalued based on current share price of UK£1.40. Our fair value estimate is 5.6% lower than Dr. Marten's analyst price target.

Healthcare software company Doximity (NYSE: DOCS) is showing signs it's back on the path to sustainable growth. The stock is up some 60% since its November 2022 lows, and though the latest quarterly earnings update was a mixed bag, there was plenty of good news to justify the rally. The company is conservatively forecasting 20% growth in fiscal 2024 and calling for revenue of at least $500 million.

Doximity (DOCS) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate. This compares to earnings of $0.17 per share.

Doximity (NYSE: DOCS) dipped more than 10% the morning after it reported results from its fiscal third quarter that ended on Dec. 31, 2022. The company revised its forward-looking guidance downward, and the market made a knee-jerk reaction. Luckily, Doximity had plenty of encouraging news to share as well.